Changshan Pharmaceutical issued an announcement on unusual share-price movements after its stock recorded a cumulative closing-price deviation decline of more than 30% over three consecutive trading days, meeting the Shenzhen Stock Exchange’s criteria for abnormal trading volatility.
According to Jin10, the company said its marketing authorization application for its ebronatide injection, intended to treat type 2 diabetes, remained under regulatory review. Changshan Pharmaceutical said it was submitting additional materials in line with requirements from the Center for Drug Evaluation under China’s National Medical Products Administration, and the review had not yet been completed.
The company said there was currently no definitive conclusion on whether the product would be approved for listing. It added that both the final review outcome and the timing for completion of the review remained uncertain.
Changshan Pharmaceutical Shares Trigger Abnormal Trading Alert After Three-Day Drop
2026-06-17 08:42:56
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
